Teva autoimmune antibody notches ph. 2 win in celiac disease
📍 Where it landed
Teva announced that its anti‑IL‑15 antibody met the primary endpoint in a Phase IIa mid‑stage study for celiac disease. The positive result was widely reported as a single‑shot success and prompted a surge in the company’s stock.
Epilogue added 37d ago, after coverage quieted.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
What happened
- Velocity & Diffusion: Coverage escalated across 9 distinct news outlets with 9 published articles, achieving a live velocity of 7.
- Predictive Outlook: Newsylist algorithmic models forecast this story will remain a dominant headline through tomorrow.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
"Teva autoimmune antibody notches ph. 2 win in celiac disease" developed substantial multi-source reporting across the Business sector, tracked across 9 distinct newsrooms by Newsylist.
Key reporting was led by Endpoints News, finance.yahoo.com, FirstWord Pharma and Reuters. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.
Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 37d ago.
The reporting (9)
-
-
-
-
-
-
-
-
-
Teva autoimmune antibody notches ph. 2 win in celiac disease Fierce Biotech · 57d ago broke it first
Questions people are asking
What drove coverage for Teva autoimmune antibody notches ph. 2 win in celiac disease?
Coverage spiked when 9 independent newsrooms published 9 verified reports during this coverage cycle.
How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.